First-Line Osimertinib for Poor Performance Status Patients with EGFR Mutant Non-Small Cell Lung Cancer
Latest Information Update: 16 Oct 2024
At a glance
- Drugs Osimertinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms OPEN
Most Recent Events
- 08 Jul 2024 New trial record
- 04 Jun 2024 Primary endpoint has been met. (Objective response rate), according to results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.